Prebiopsy multiparametric MRI of the prostate: The end of randomized biopsies?;IRM mutiparamétrique de la prostate avant biopsies : La fin des biopsies systématisées?

Progres en Urologie

Volumn 22, Issue 10, 2012, Pages 583-589

  Belas, O ^a   Klap, J ^a   Cornud, F ^a   Beuvon, F ^a   Peyromaure, M ^a   Zerbib, M ^a   Delongchamps, N B ^a  

^a Université Paris Descartes ^*  (France)

Author keywords

Multiparametric MRI; Prostate cancer; Targeted biopsies

Indexed keywords

AGED; ARTICLE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROSPECTIVE STUDY; PROSTATE; PROSTATE TUMOR;

AGED; BIOPSY, NEEDLE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84865551035     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2012.03.007     Document Type: Article

References (20)

1. Noldus J., Graefen M., Haese A., Henke R.P., Hammerer P., Huland H. Stage migration in clinically localized prostate cancer. Eur Urol 2000, 38:74-78.
2. Epstein J.I., Walsh P.C., Carmichael M., Brendler C.B. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994, 271:368-374.
3. Stamey T.A., Freiha F.S., McNeal J.E., Redwine E.A., Whittemore A.S., Schmid H.P. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993, 71:933-938.
4. Haas G.P., Delongchamps N.B., Jones R.F., Chandan V., Serio A.M., Vickers A.J., et al. Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst 2007, 99:1484-1489.
5. Mozer P., Baumann M., Chevreau G., Moreau-Gaudry A., Bart S., Renard-Penna R., et al. Mapping of transrectal ultrasonographic prostate biopsies: quality control and learning curve assessment by image processing. J Ultrasound Med 2009, 28:455-460.
6. Boccon-Gibod L.M., de Longchamps N.B., Toublanc M., Boccon-Gibod L.A., Ravery V. Prostate saturation biopsy in the reevaluation of microfocal prostate cancer. J Urol 2006, 176:961-963.
7. Lucia M.S., Darke A.K., Goodman P.J., La Rosa F.G., Parnes H.L., Ford L.G., et al. Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res 2008, 1:167-173.
8. Schröder F.H., Hugosson J., Roobol M.J., Tammela T.L., Ciatto S., Nelen V., et al. ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-1328.
9. Villers A., Puech P., Mouton D., Leroy X., Ballereau C., Lemaitre L. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 2006, 176:2432-2437.
10. Delongchamps N.B., Rouanne M., Flam T., Beuvon F., Liberatore M., Zerbib M., et al. Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging. BJU Int 2011, 107:1411-1418.
11. Bittencourt L.K., Barentsz J.O., de Miranda L.C., Gasparetto E.L., Prostate M.R.I. diffusion-weighted imaging at 1.5T correlates better with prostatectomy Gleason grades than TRUS-guided biopsies in peripheral zone tumours. Eur Radiol 2012, 22:468-475.
12. Delongchamps N.B., Beuvon F., Eiss D., Flam T., Muradyan N., Zerbib M., et al. Multiparametric MRI is helpful to predict tumor focality, stage, and size in patients diagnosed with unilateral low-risk prostate cancer. Prostate Cancer Prostatic Dis 2011, 14:232-237.
13. Ouzzane A., Coloby P., Mignard J.P., Allegre J.P., Soulie M., Rebillard X., et al. Committee of Infectious Diseases of the French Association of Urology (CIAFU); Committee of Cancerology of the French Association of Urology (CCAFU). Recommendations for best practice for prostate biopsy. Prog Urol 2011, 21:18-28.
14. Haute Autorité de Santé (HAS) : recommandations pour la pratique clinique. éléments d'information des hommes envisageant la réalisation d'un dépistage individuel du cancer de la prostate. Anaes 2004. http://www.has-sante.fr/portail/upload/docs/application/pdf/information_kp_recommandations-2006.pdf.
15. Dynamique d'évolution des taux de mortalité des principaux cancers en France. Institut National du Cancer. Novembre 2010. http://www.e-cancer.fr/.
16. Nam R.K., Saskin R., Lee Y., Liu Y., Law C., Klotz L.H., et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010, 183:963-968.
17. Turkbey B., Mani H., Shah V., Rastinehad A.R., Bernardo M., Pohida T., et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol 2011, 186:1818-1824.
18. Park B.K., Park J.W., Park S.Y., Kim C.K., Lee H.M., Jeon S.S., et al. Prospective evaluation of 3-T MRI performed before initial transrectal ultrasound-guided prostate biopsy in patients with high prostate-specific antigen and no previous biopsy. AJR Am J Roentgenol 2011, 197:W876-W881.
19. Haffner J., Lemaitre L., Puech P., Haber G.P., Leroy X., Jones J.S., et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int 2011, 108:171-178.
20. Ahmed H.U., Kirkham A., Arya M., Illing R., Freeman A., Allen C., et al. Is ittime to consider a role for MRI before prostate biopsy?. Nat Rev Clin Oncol 2009, 6:197-206.